VANCOUVER, British Columbia, May 6, 2005 (PRIMEZONE) -- Several major blood services groups have been carefully monitoring the extensive testing program currently being conducted by ProtoKinetix (OTCBB:PKTX) in Quebec. Due to the positive results ProtoKinetix has received on cell stabilization of red blood cells, platelets and tissues, the Company has been approached by two of the world's leading blood research facilities.
ProtoKinetix CEO, Dr. John Todd, expects to formalize an extensive agreement with a major European institution within the next month. This world recognized institution will be extending the testing of synthetic AFGP into the areas of the biological function of blood platelets, red blood cells and other blood components. Full details on this extensive program will be released as the agreement is finalized.
About ProtoKinetix:
ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President